Yihu Zheng

Dr. Yihu Zheng


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2016 in Liver International
Verified
Journal Article
Closed access
PDF file
YZYihu Zheng
Yihu Zheng
WHWei‐Jian Hu
Wei‐Jian Hu
BCBi‐Cheng Chen
Bi‐Cheng Chen
TGTan‐Hooi‐Min Grahn
Tan‐Hooi‐Min Grahn
YZYan‐Rong Zhao
Yan‐Rong Zhao
QZQi‐Yu Zhang
Qi‐Yu Zhang

10 February 2021 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
LLLifang Luo
Lifang Luo
WSWenjing Sun
Wenjing Sun
WZWeijian Zhu
Weijian Zhu
SLShuhan Li
Shuhan Li
WZWenqi Zhang
Wenqi Zhang
YZYihu Zheng
Yihu Zheng
Cisplatin is one of the most effective chemotherapy drugs and is widely used in the treatment of cancer, including hepatocellular carcinoma (HCC) and cervical cancer, but its therapeutic benefit is limited by the development of resistance. Our previous studies demonstrated that BCAT1 promoted cell proliferation and decreased cisplatin sensitivity in HCC cells. However, the exact role and mechanism of how BCAT1 is involved in cisplatin cytotoxicity remain undefined. In this study, we revealed that cisplatin triggered autophagy in cancer cells, with an increase in BCAT1 expression. The cisplatin-induced up-regulation of BCAT1 decreased the cisplatin sensitivity by regulating autophagy through the mTOR signaling pathway. In addition, branched-chain amino acids or leucine treatment inhibited cisplatin- or BCAT1-mediated autophagy and increased cisplatin sensitivity by activating mTOR signaling in cancer cells. Moreover, inhibition of autophagy by chloroquine increased cisplatin sensitivity in vivo. Also, the knockdown of BCAT1 or the administration of leucine activated mTOR signaling, inhibited autophagy, and increased cisplatin sensitivity in cancer cells in vivo. These findings demonstrate a new mechanism, revealing that BCAT1 decreases cisplatin sensitivity in cancer cells by inducing mTOR-mediated autophagy via branched-chain amino acid leucine metabolism, providing an attractive pharmacological target to improve the effectiveness of chemotherapy.

4 March 2014 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
YZYihu Zheng
Yihu Zheng
LYLi‐Hui Yin
Li‐Hui Yin
TGTan Hooi Min Grahn
Tan Hooi Min Grahn
AYAi‐Fang Ye
Ai‐Fang Ye
YZYan‐Rong Zhao
Yan‐Rong Zhao
QZQi‐Yu Zhang
Qi‐Yu Zhang

3 January 2021 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
YZYihu Zheng
Yihu Zheng
QZQingqing Zhou
Qingqing Zhou
CZChang Zhao
Chang Zhao
JLJunjian Li
Junjian Li
ZYZhengping Yu
Zhengping Yu
QZQiandong Zhu
Qiandong Zhu
ATP citrate lyase (ACLY), a key enzyme in the metabolic reprogramming of many cancers, is widely expressed in various mammalian tissues. This study aimed to evaluate the effects and mechanisms of ACLY and its inhibitor BMS‐303141 on hepatocellular carcinoma (HCC). In this study, ACLY was highly expressed in HCC tissues, especially in HepG2 and Huh7 cells, but was down‐regulated in Hep3B and HCC‐LM3 cells. Besides, ACLY knockdown inhibited HepG2 proliferation and clone formation, while opposite result was noticed in HCC‐LM3 cells with ACLY overexpression. Moreover, ACLY knockdown impeded the migration and invasion abilities of HepG2 cells. Similarly, BMS‐303141 suppressed HepG2 and Huh‐7 cell proliferation. The p‐eIF2α, ATF4, CHOP p‐IRE1α, sXBP1 and p‐PERK were activated in HepG2 cells stimulated by BMS‐303141. In cells where ER stress was induced, ATF4 was involved in BMS‐303141‐mediated cell death procession, and ATF4 knockdown reduced HCC cell apoptosis stimulated by BMS‐303141. In a mouse xenograft model, combined treatment with BMS‐303141 and sorafenib reduced HepG2 tumour volume and weight. In addition, ACLY expression was associated with HCC metastasis and tumour‐node‐metastases staging. Survival analysis and Cox proportional hazards regression model showed that overall survival was lower in HCC patients with high ACLY expression; AFP level, TNM staging, tumour size and ACLY expression level were independent risk factors affecting their overall survival. In conclusion, ACLY might represent a promising target in which BMS‐303141 could induce ER stress and activate p‐eIF2α/ATF4/CHOP axis to promote apoptosis of HCC cells, and synergized with sorafenib to enhance the efficacy of HCC treatment.

2 June 2021 in Oncogene
Verified
Journal Article
Closed access
PDF file
YWYi Wang
Yi Wang
HYHaitao Yu
Haitao Yu
XXXiaozai Xie
Xiaozai Xie
TDTuo Deng
Tuo Deng
LYLongyun Ye
Longyun Ye
GCGang Chen
Gang Chen

15 February 2015 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
FYFu-Xiang Yu
Fu-Xiang Yu
WHWei-Jian Hu
Wei-Jian Hu
BHBin He
Bin He
YZYihu Zheng
Yihu Zheng
QZQi-Yu Zhang
Qi-Yu Zhang
LCLin Chen
Lin Chen
Bone marrow-derived stem cells (BMSCs) are locally adjacent to the tumor tissues and may interact with tumor cells directly. The purpose of this study was to explore the effects of BMSCs on the proliferation and invasion of osteosarcoma cells in vitro and the possible mechanism involved. BMSCs were co-cultured with osteosarcoma cells, and CCK-8 assay was used to measure cell proliferation. The ELISA method was used to determine the concentration of stromal cell-derived factor-1 (SDF-1) in the supernatants. Reverse transcription polymerase chain reaction (RT-PCR) was performed to detect the expression of CXCR4 in osteosarcoma cells and BMSCs. Matrigel invasion assay was performed to measure tumor cell invasion. SDF-1 was detected in the supernatants of BMSCs, but not in osteosarcoma cells. Higher CXCR4 mRNA levels were detected in the osteosarcoma cell lines compared to BMSCs. In addition, conditioned medium from BMSCs can promote the proliferation and invasion of osteosarcoma cells, and AMD3100, an antagonist for CXCR4, can significantly downregulate these growth-promoting effects. BMSCs can promote the proliferation and invasion of osteosarcoma cells, which may involve the SDF-1/CXCR4 axis.